Nuvation Bio Inc. (NUVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NUVB Price/Volume Stats
| Current price | $1.57 | 52-week high | $4.31 |
| Prev. close | $1.61 | 52-week low | $1.52 |
| Day low | $1.56 | Volume | 618,468 |
| Day high | $1.63 | Avg. volume | 554,413 |
| 50-day MA | $1.67 | Dividend yield | N/A |
| 200-day MA | $2.06 | Market Cap | 343.52M |
NUVB Stock Price Chart Interactive Chart >
Nuvation Bio Inc. (NUVB) Company Bio
Nuvation Bio Inc. operates as a bio-pharmaceutical company. The Company focuses on developing oncology medicines that will improve patient lives by addressing drug resistance. Nuvation Bio serves patients worldwide.
Latest NUVB News From Around the Web
Below are the latest news stories about NUVATION BIO INC that investors may wish to consider to help them evaluate NUVB as an investment opportunity.
Nuvation Bio Insider Ups Holding During Year \Viewing insider transactions for Nuvation Bio Inc.'s ( NYSE:NUVB ) over the last year, we see that insiders were net... |
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business UpdateNEW YORK, May 04, 2023--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2023, and provided a business update. |
12 Best Biotech Stocks To Buy Under $20In this piece, we will take a look at the 12 best biotechnology stocks to buy under $20. For more stocks, head on over to 5 Best Biotech Stocks To Buy Under $20. The biotechnology industry is one of the hottest sectors right now, particularly in the aftermath of the coronavirus pandemic since it was […] |
The 7 Worst Stocks to Buy NowWith the market reeling from the banking crisis, even hardened gamblers should avoid these worst stocks to buy now. |
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNEW YORK, March 15, 2023--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. |
NUVB Price Returns
| 1-mo | -2.48% |
| 3-mo | -15.14% |
| 6-mo | -20.71% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -18.23% |
| 2022 | -77.41% |
| 2021 | -27.35% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...